share_log

DiaMedica Therapeutics Doses First Patient Relaunch Of Pivotal Phase 2/3 ReMEDy2 Trial Of DM199 For Acute Ischemic Stroke

Benzinga ·  Apr 18 04:08
DiaMedica Therapeutics Doses First Patient Relaunch Of Pivotal Phase 2/3 ReMEDy2 Trial Of DM199 For Acute Ischemic Stroke
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment